🔎 Trials Near Me

Beranda › Kanker Darah › Texas › Dallas

Uji klinis Kanker Darah di Dallas, TX

12 studi untuk Kanker Darah mencari peserta di lokasi sekitar Dallas (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Menerima pesertaFase 3
  • Texas Oncology-Baylor Sammons Cancer Center ( Site 0062), Dallas
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT03486873

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Menerima pesertaFase 2
  • UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730), Dallas
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT04728893

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Menerima pesertaFase 1
  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT03816345

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Menerima pesertaFase 1/2
  • Baylor Scott & White Health, Dallas
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT04588922

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Menerima pesertaFase 3
  • Texas Oncology-Presbyterian Cancer Center, Dallas
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Menerima pesertaFase 1
  • Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT06001788

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Menerima pesertaStudi observasional
  • Medical City Dallas, Dallas
  • Children's Medical Center Dallas, Dallas
Semua usia · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT01351545

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Menerima pesertaFase 1
  • UT Southwestern Medical Center, Dallas
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jun 2026 · NCT02074839

A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

Menerima pesertaFase 3
  • Medical City Dallas Hospital, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Usia 2 hingga 18 · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT05711667

Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant

Menerima peserta
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Usia 6 hingga 29 · Semua jenis kelamin · Diperbarui 4 Mei 2026 · NCT04678427

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Menerima pesertaFase 1
  • UT Southwestern - Simmons Cancer Center, Dallas
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Mar 2026 · NCT05735184

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Menerima pesertaFase 1
  • University of Texas, Southwestern, Dallas
Usia 1 hingga 21 · Semua jenis kelamin · Diperbarui 6 Des 2024 · NCT05476770

Uji klinis Kanker Darah di kota lain

Studi lain di Dallas

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.